SentientLight Seeks US$10M After Peer-Reviewed PEMF Study Validates Non-Drug Pain Relief

Funding to scale PEMF device production, complete FDA submission, continue clinical studies, and launch targeted digital marketing initiatives.

HAYDEN, Idaho, Aug. 13, 2025 /PRNewswire/ -- SentientLight (www.sentientlight.com) has announced a capital development plan beginning with an initial tranche of approximately US$2 million toward a targeted US$10 million raise. Once secured, these funds will support:

• U.S.-based manufacturing scale-up
• FDA submission process
• Additional clinical pilots
• R&D for next-generation wearable devices
• Continued research into potential applications in insomnia, Lyme disease, and arthritis (currently investigational and not cleared or approved by the FDA)
• Digital marketing initiatives to drive awareness and sales of the company's devices

The funding push follows publication of a peer-reviewed clinical study showing that SentientLight's pulsed electromagnetic field (PEMF) therapy device achieved a 20% reduction in pain in knee osteoarthritis patients — aligning with growing regulatory support for non-drug pain solutions.

Timely Context

FDA Approval Signals Shift
In January 2025, the U.S. Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid analgesic Journavx for acute pain — a milestone highlighting growing regulatory support for non-drug pain pathways (FDA press announcement) and (Reuters coverage).

Market Growth Creates Opportunity
Rising rates of arthritis, insomnia, and Lyme disease are contributing to sustained growth in global market demand, creating conditions that could enable therapies such as SentientLight's PEMF technology to become available to patients in the future, if supported by additional clinical evidence and regulatory clearance, the company said.

Peer-Reviewed Clinical Study Results
A 10-patient, open-label pilot study conducted at Apollo Institute of Medical Sciences & Research in Hyderabad, India, and published in the Asian Journal of Pharmaceutical & Clinical Research (Vol 18-3, DOI 10.22159/ajpcr.2025v18i3.53722), evaluated SentientLight's PEMF device for early-stage knee osteoarthritis.

Key Outcomes after 12 Weeks of One-Hour Sessions:

• 20% reduction in pain
• 17% decrease in stiffness
• 8° improvement in joint mobility

"The improvements we observed in this pilot study are promising, particularly given the non-invasive, non-drug nature of the therapy," said Dr. Abhidya Reddy, Apollo Institute of Medical Sciences & Research, who oversaw the trial. "While further studies are needed, the results suggest this approach could offer patients a valuable new option for managing chronic pain."

Device Capabilities & Recognition

• Peak output: 150,000 Gauss
• Frequency sweep: 2 Hz to 10 kHz (at the high end of devices in its category, the company said)
• Recognition: Named "Best Frequency Range" among PEMF devices by Medical News Today
• IP Protection: Patent No. ZL201821461327.9 for its dual-coil PEMF design

Founder's Story
Founder and CEO Larry Langdon developed the device after years of managing chronic pain from Lyme disease.

• 30-year engineering veteran with past roles at Boeing, Intel, and Microsoft.
• Expertise in embedded systems and power electronics.

"After a decade of suffering from Lyme disease and the chronic pain it left behind — and finding little relief through traditional medicine — I set out to create a different kind of solution," Langdon said. "This company was born from my own search for a non-drug approach that could help where other methods had failed me, and our mission is to make this therapy available to people with similar conditions, subject to further clinical validation and regulatory review."

Market Opportunity
The non-drug pain relief market is projected to reach ~US$773 million by 2030. Combined therapeutic and testing markets for arthritis, insomnia, and Lyme disease exceed US$38.7 billion:

• Rheumatoid arthritis therapeutics: US$25 billion in 2023, projected US$36.4 billion by 2030
• Insomnia therapeutics: US$2.89 billion in 2024, projected US$3.74 billion by 2030
• Lyme disease testing: US$10.85 billion in 2023

SentientLight plans to expand into these markets in response to rising demand for non-drug pain relief solutions.

Next Steps
SentientLight invites strategic partners and investors to join in advancing non-drug pain relief options worldwide.

• Proceeds will support U.S. manufacturing, FDA submission, and additional clinical pilots.
• Placebo-controlled insomnia trial planned for 2026.

For more information:

• Visit https://www.sentientlight.com
• Download the full study PDF
• Email: [email protected]

About SentientLight LLC
Larry Langdon founded SentientLight LLC in 2018. He has 30+ years of experience developing technologies for Boeing, National Semiconductor, Intel, Microsoft, and classified projects requiring special clearance for high-level applications. Utilizing his B.S. in electrical engineering, he has extensive experience in software, hardware, integration, instrumentation, product testing and embedded designs, including the first FDA-approved defibrillator.

Contact:
Larry Langdon, SentientLight, [email protected]
Khartik, SentientLight, [email protected]
+1 208-512-7775

Sources 
(Source 1) SentientLight Element – 12-week knee-osteoarthritis pilot (https[:]//www.sentientlight.com/Portals/0/Study/Sentient%20Element%20-%20Arthritis%20Study.pdf) 

(Source 2) Medical News Today – "5 Best PEMF Therapy Devices" (https[:]//www.medicalnewstoday.com/articles/pemf-therapy-device) 

(Source 3) SentientLight – comparison chart (https[:]//www.sentientlight.com/pemfdevicescomparison) 

(Source 4) TechSci Research – Global PEMF devices market forecast (https[:]//www.techsciresearch.com/report/pulse-electromagnetic-field-therapy-devices-market/27447.html) 

(Source 5) PRWeb – SentientLight background and Larry Langdon résumé (Boeing, Intel, National Semi, Microsoft) (https[:]//www.prweb.com/releases/sentientlight-llc-introduces-the-sentient-element-the-world-s-highest-intensity-and-most-flexible-pemf-device-870440578.html) 

(Source 6) Grand View Research – Rheumatoid Arthritis Therapeutics Market (https[:]//www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market) 

(Source 7) Grand View Research – Insomnia Therapeutics Market (https[:]//www.grandviewresearch.com/industry-analysis/insomnia-therapeutics-market) 

(Source 8) Grand View Research – Lyme Disease Testing Market (https[:]//www.grandviewresearch.com/industry-analysis/lyme-disease-testing-market-report)

Forward-Looking Statements: This press release contains forward-looking statements regarding future events and the future performance of SentientLight, including statements relating to the company's funding plans, regulatory submissions, clinical trials, and market opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. SentientLight undertakes no obligation to update or revise these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sentientlight-seeks-us10m-after-peer-reviewed-pemf-study-validates-non-drug-pain-relief-302528533.html

SOURCE SentientLight